帕罗西汀联合奥氮平治疗难治性抑郁症对照研究

目的：探讨帕罗西汀联合奥氮平治疗难治性抑郁症的临床疗效和安全性。方法将78例难治性抑郁症患者随机分为两组，每组39例，均口服帕罗西汀治疗，在此基础上研究组联合奥氮平治疗，观察8周。采用汉密顿抑郁量表、汉密顿焦虑量表评定临床疗效，副反应量表评定不良反应。结果治疗2周末起两组汉密顿抑郁量表、汉密顿焦虑量表总分均较治疗前显著性下降（P＜0．01），研究组治疗各时段评分均显著低于对照组（P＜0．01）；治疗8周末研究组有效率为87．2％，对照组为66．7％，研究组显著高于对照组（χ2＝4．62，P＜0．05）。研究组不良反应发生率为43．6％，对照组为46．2％，两组比较差异无显著性（χ2＝0．05，P＞0．05）。结论帕罗西汀联合奥氮平治疗难治性抑郁症起效快，疗效显著，安全性高，依从性好，优于单用帕罗西汀治疗。

A control study of paroxetine plus olanzapine in the treatment of treatment-resistant depression

Objective To explore the clinical efficacy and safety of paroxetine combined with olanzapine in the treatment of treatment-resistant depression （TRD） .Methods Seventy-eight TRD patients were ran-domly assigned to two groups of 39 ones each ,both groups took orally paroxetine ,and on this basis re-search group was plus olanzapine for 8 weeks .Efficacies were assessed with the Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HAMA ） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results The HAMD and HAMA total scores of both groups lowered more sig-nificantly since the end of the 2nd week compared with pretreatment （P〈0 .01） ,so did those in research than control group in the corresponding period （P〈0 .01）;at the end of the 8th week effective rate was re-spectively 87 .2% in research and 66 .7% in control group ,the former was significantly higher than the lat-ter （χ2 = 4 .62 ,P〈 0 .05） .There was no significant group difference in incidence of adverse reaction （43 .6% vs .46 .2% ,χ2 =0 .05 ,P〉0 .05） .Conclusion Paroxetine combined with olanzapine takes effect more rapidly and has an evident effect ,higher safety and better compliance compared with single paroxe-tine in the treatment of treatment-resistant depression .